Leerink Partners analyst Faisal Khurshid has reiterated their bullish stance on SNYNF stock, giving a Buy rating on July 28.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Faisal Khurshid has given his Buy rating due to a combination of factors including the promising outlook for Sanofi’s amlitelimab, which is currently undergoing Phase 3 trials for atopic dermatitis. The trials, COAST 1 and SHORE, are anticipated to yield successful results due to their placebo-controlled design and supportive Phase 2b data, positioning amlitelimab as a potential multi-billion-dollar blockbuster for patients who do not respond to first-line biologics like Dupixent.
The trials have a primary endpoint at 24 weeks, which is longer than the standard 16-week duration for approved biologics, suggesting that amlitelimab’s efficacy may continue to deepen beyond this period. Although the Q12W dose is less validated, it presents a unique differentiation opportunity. Sanofi is also exploring amlitelimab in additional trials, which could further strengthen its market position. These factors contribute to Khurshid’s optimistic outlook and Buy rating for Sanofi’s stock.
In another report released on July 28, Bernstein also maintained a Buy rating on the stock with a €124.00 price target.